Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials

Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4

(2016) T. Blevins et al.   DIABETES OBESITY & METABOLISM

Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial

(2016) M. J. Davies et al.   DIABETES OBESITY & METABOLISM

Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3

(2016) R. M. Bergenstal et al.   DIABETES OBESITY & METABOLISM

A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1

(2016) S. Garg et al.   DIABETES OBESITY & METABOLISM

Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study

(2016) S. Garg et al.   DIABETES OBESITY & METABOLISM

Insulin Delivery Into the Peripheral Circulation: A Key Contributor to Hypoglycemia in Type 1 Diabetes

(2015) Justin M. Gregory et al.   DIABETES

Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5

(2015) John B. Buse et al.   DIABETES CARE

Minimizing Hypoglycemia in Diabetes

(2015)   DIABETES CARE

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

(2015) R. Ritzel et al.   DIABETES OBESITY & METABOLISM

Performance of an Electronic Diary System for Intensive Insulin Management in Global Diabetes Clinical Trials

(2015) Edward J. Bastyr et al.   Diabetes Technology & Therapeutics

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

(2014) Robert R. Henry et al.   DIABETES CARE

Estimation of group means when adjusting for covariates in generalized linear models

(2014) Yongming Qu et al.   PHARMACEUTICAL STATISTICS

Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus

(2013) V. P. Sinha et al.   DIABETES OBESITY & METABOLISM

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

(2012) J. Rosenstock et al.   DIABETES CARE

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes

(2012) R. M. Bergenstal et al.   DIABETES CARE

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

(2012) R. E. Ratner et al.   DIABETES OBESITY & METABOLISM

Rate of Hypoglycemia in Insulin-Treated Patients with Type 2 Diabetes Can Be Predicted from Glycemic Variability Data

(2012) Yongming Qu et al.   Diabetes Technology & Therapeutics